A randomized phase II trial of dexamethasone versus prednisolone as secondary hormonal therapy in CRPC.
Ramachandran Venkitaraman(University of Suffolk), Chris Parker(Royal Marsden NHS Foundation Trust), Karen Thomas(Royal Glamorgan Hospital), Robert Huddart(Institute of Cancer Research), Vedang Murthy(Homi Bhabha National Institute), Ruth Woode‐Amissah(Institute of Cancer Research), Alan Horwich(Institute of Cancer Research), Johann S. de Bono(Royal Marsden NHS Foundation Trust), David P. Dearnaley(Royal Marsden NHS Foundation Trust)
Cited by 4
Related Papers
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
|New England Journal of Medicine|2013|3.3k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k